AR078675A1 - Derivados de pirazolo[3,4-d]pirimidina inhibidores de jak quinasas, composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos para el tratamiento o profilaxis de trastornos inmunologicos, inflamatorios y autoinmunes. - Google Patents
Derivados de pirazolo[3,4-d]pirimidina inhibidores de jak quinasas, composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos para el tratamiento o profilaxis de trastornos inmunologicos, inflamatorios y autoinmunes.Info
- Publication number
- AR078675A1 AR078675A1 ARP100103813A ARP100103813A AR078675A1 AR 078675 A1 AR078675 A1 AR 078675A1 AR P100103813 A ARP100103813 A AR P100103813A AR P100103813 A ARP100103813 A AR P100103813A AR 078675 A1 AR078675 A1 AR 078675A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkynyl
- alkenyl
- same
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Surgery (AREA)
- Nutrition Science (AREA)
Abstract
Reivindicacion 1: Un compuesto de formula (1) o una sal, profármaco o metabolito farmacéuticamente aceptable de éste, donde R es H o F; el anillo A es un heterociclo aromático de 5 miembros en el cual Z1, Z2 y Z3 están independientemente seleccionados del grupo integrado por C(R1), N, N(R1), O y S, con la condicion de que por lo menos uno de Z1, Z2, Z3 es N; cada R1 es independientemente H, halogeno, CN; C(O)OR2, OR2; C(O)R2; C(O)N(R2R2; S(O)2N(R2R2a); S(O)N(R2R2a); S(O)2R2; S(O)R2; N(R2)S(O)2N(R2aR2b); N(R2)S(O)N(R2aR2b); SR2; N(R2R2a); NO2; OC(O)R2; N(R2)C(O)R2a; N(R2)S(O)2R2a; N(R2)S(O)R2a; N(R2)C(O)N(R2aR2b); N(R2)C(O)OR2a; OC(O)N(R2R2a); T1; alquilo C1-6; alquenilo C2-6; o alquinilo C2-6, donde alquilo C1-6; alquenilo C2-6 y alquinilo C2-6 están sustituidos opcionalmente con uno o más R3, que son iguales o diferentes; R2, R2a, R2b están independientemente seleccionados del grupo integrado por H; T1; alquilo C1-6; alquenilo C2-6; y alquinilo C2-6, donde alquilo C1-6; alquenilo C2-6; y alquinilo C2-6 están sustituidos opcionalmente con uno o más R3, que son iguales o diferentes; R3 es halogeno; CN; C(O)OR4; OR4; C(O)R4; C(O)N(R4R4a); S(O)2N(R4R4a); S(O)N(R4R4a); S(O)2R4; S(O)R4; N(R4)S(O)2N(R4aRb); N(R4)S(O)2N(R4aR4b); SR4; N(R4aR4b); NO2; OC(O)R4; N(R4)C(O)R4a; N(R4)S(O)2R4a; N(R4)S(O)R4a; N(R4)C(O)N(R4aR4b); N(R4)C(O)OR4a; OC(O)N(R4R4a); o T1; R4, R4a, R4b están independientemente seleccionados del grupo integrado por H; T1; alquilo C1-6; alquenilo C2-6; y alquinilo C2-6, donde alquilo C1-6; alquenilo C2-6; y alquinilo C2-6 están sustituidos opcionalmente con uno o más halogeno, que son iguales o diferentes; T1 es cicloalquilo C3-7 o heterociclilo de 4 a 7 miembros saturado, donde T1 está opcionalmente sustituido con uno o más R10, que son iguales o diferentes; Y es (C(R5R5a))n; n es 0, 1, 2, 3 o 4; R5, R5a están independientemente seleccionados del grupo integrado por H; y alquilo C1-6 no sustituido; o forman en conjunto oxo (=O); opcionalmente, R5, R5a se unen para formar un cicloalquilo C3-7 no sustituido; X1 es C(R6) o N; X2 es C(R6a) o N; X3 es C(R6b) o N; X4 es C(R6c) o N; X5 es C(R6d) o N, con la condicion de que como máximo dos de X1, X2, X3, X4, X5 son N; R6, Ra, R6b, R6c, R6d están independientemente seleccionados del grupo integrado por H; halogeno; CN; C(O)OR7; OR7; C(O)R7; C(O)N(R7R7a); S(O)2N(R7R7a); S(O)N(R7R7a); S(O)2R7; S(O)R7; N(R7)S(O)2N(R7a7b); N(R7)S(O)N(R7aR7b); SR7; N(R7aR7b); NO2; OC(O)R7; N(R7)C(O)R7a; N(R7)S(O)2R7a; N(R7)S(O)R7a; N(R7)C(O)N(R7aR7b); N(R7)C(O)OR7a; OC(O)N(R7R7a); o T2; alquilo C1-6; alquenilo C2-6; y alquinilo C2-6; donde alquilo C1-6; alquenilo C2-6; y alquinilo C2-6 están sustituidos opcionalmente con uno o más R11, que son iguales o diferentes; opcionalmente uno de los pares R6/R6a, R6a/R6b se une para formar un anillo T3; R7, R7a, R7b están independientemente seleccionados del grupo integrado por H; T2; alquilo C1-6; alquenilo C2-6; y alquinilo C2-6, donde alquilo C1-6; alquenilo C2-6; y alquinilo C2-6 están sustituidos opcionalmente con uno o más R8, que son iguales o diferentes; R8 es halogeno; CN; C(O)OR9; OR9; C(O)R9; C(O)N(R9R9a); S(O)2N(R9R9a); S(O)N(R9R9a); S(O)2R9; S(O)R9; N(R9)S(O)2N(R9a9b); N(R9)S(O)2N(R9aR9b); SR9; N(R9aR9b); NO2; OC(O)R9; N(R9)C(O)R9a; N(R9)S(O)2R9a; N(R9)S(O)R9a; N(R9)C(O)N(R9aR9b); N(R9)C(O)OR9a; OC(O)N(R9R9a); o T2; R9, R9a, R9b están independientemente seleccionados del grupo integrado por H; T2 alquilo C1-6; alquenilo C2-6, y alquinilo C2-6, donde alquilo C1-6, alquenilo C2-6, y alquinilo C2-6 están sustituidos opcionalmente con uno o más R12, que son iguales o diferentes; R10 es halogeno; CN; C(O)OR13; OR13; oxo (=O), donde el anillo está saturado por lo menos parcialmente; C(O)R13; C(O)N(R13R13a); S(O)2N(R13R13a); S(O)N(R13R13a); S(O)2R13; S(O)R13; N(R13)S(O)2N(R13a13b); N(R13)S(O)N(R13aR13b); SR13; N(R13aR13b); NO2; OC(O)R13; N(R13)C(O)R13a; N(R13)S(O)2R13a; N(R13)S(O)R13a; N(R13)C(O)N(R13aR13b); N(R13)C(O)OR13a; OC(O)N(R13R13a); alquilo C1-6; alquenilo C2-6, y alquinilo C2-6, donde alquilo C1-6, alquenilo C2-6, y alquinilo C2-6 están sustituidos opcionalmente con uno o más R14, que son iguales o diferentes; R13, R13a, R3b están independientemente seleccionados del grupo integrado por H; alquilo C1-6, alquenilo C2-6; y alquinilo C2-6, donde alquilo C1-6; alquenilo C2-6; y alquinilo C2-6 están sustituidos opcionalmente con uno o más R14, que son iguales o diferentes; R11, R12 están independientemente seleccionados del grupo integrado por halogeno; CN; C(O)OR15; OR15; C(O)R15; C(O)N(R15R15a); S(O)2N(R15R15a); S(O)N(R15R15a); S(O)2R15; S(O)R15; N(R15)S(O)2N(R15a15b); N(R15)S(O)N(R15aR15b); SR15; N(R15aR15b); NO2; OC(O)R15; N(R15)C(O)R15a; N(R15)S(O)2R15a; N(R15)S(O)R15a; N(R15)C(O)N(R15aR15b); N(R15)C(O)OR15a; OC(O)N(R15R15a); o T2; R15, R15a, R15b están independientemente seleccionados del grupo integrado por H; T2; alquilo C1-6; alquenilo C2-6, y alquinilo C2-6, donde alquilo C1-6, alquenilo C2-6, y alquinilo C2-6 están sustituidos opcionalmente con uno o más halogenos que son iguales o diferentes; R14 es halogeno; CN; C(O)OR16; OR16; C(O)R16; C(O)N(R16R16a); S(O)2N(R16R16a); S(O)N(R16R16a); S(O)2R16; S(O)R16; N(R16)S(O)2N(R16a16b); N(R16)S(O)N(R16aR16b); SR16; N(R16aR16b); NO2; OC(O)R16; N(R16)C(O)R16a; N(R16)S(O)2R16a; N(R16)S(O)R16a; N(R16)C(O)N(R16aR16b); N(R16)C(O)OR16a; o OC(O)N(R16R16a); R16, R16a, R16b están independientemente seleccionados del grupo integrado por H; alquilo C1-6; alquenilo C2-6, y alquinilo C2-6, donde alquilo C1-6, alquenilo C2-6, y alquinilo C2-6 están sustituidos opcionalmente con uno o más halogenos que son iguales o diferentes; T2 es fenilo; naftilo; indenilo; indanilo; cicloalquilo C3-7; heterociclilo de 4 a 7 miembros; o heterobiciclilo de 7 a 11 miembros, donde T2 está opcionalmente sustituido con uno o más R17, que son iguales o diferentes; T3 es fenilo; cicloalquilo C3-7; o heterociclilo de 4 a 7 miembros, donde T3 está opcionalmente sustituido con uno o más R18, que son iguales o diferentes; R17, R18 están independientemente seleccionados del grupo integrado por halogeno; CN; C(O)OR19; OR19; oxo (=O), donde el anillo está saturado por lo menos parcialmente; C(O)R19; C(O)N(R19R19a); S(O)2N(R19R19a); S(O)N(R19R19a); S(O)2R19; S(O)R19; N(R19)S(O)2N(R19a19b); N(R19)S(O)N(R19aR19b); SR19; N(R19aR19b); NO2; OC(O)R19; N(R19)C(O)R19a; N(R19)S(O)2R19a; N(R19)S(O)R19a; N(R19)C(O)N(R19aR19b); N(R19)C(O)OR19a; OC(O)N(R19R19a); alquilo C1-6; alquenilo C2-6, y alquinilo C2-6, donde alquilo C1-6, alquenilo C2-6, y alquinilo C2-6 están sustituidos opcionalmente con uno o más R20, que son iguales o diferentes: R19, R19a, R19b están independientemente seleccionados del grupo integrado por H; alquilo C1-6, alquenilo C2-6, y alquinilo C2-6, donde alquilo C1-6; alquenilo C2-6; y alquinilo C2-6 están sustituidos opcionalmente con uno o más R20, que son iguales o diferentes; R20 es halogeno; CN; C(O)OR21; OR21; C(O)R21; C(O)N(R21R21a); S(O)2N(R21R21a); S(O)N(R21R21a); S(O)2R21; S(O)R21; N(R21)S(O)2N(R21a21b); N(R21)S(O)N(R21aR21b); SR21; N(R21aR21b); NO2; OC(O)R21; N(R21)C(O)R21a; N(R21)S(O)2R21a; N(R21)S(O)R21a; N(R21)C(O)N(R21aR21b); N(R21)C(O)OR21a; o OC(O)N(R21R21a); R21, R21a, R21b están independientemente seleccionados del grupo integrado por H; alquilo C1-6; alquenilo C2-6, y alquinilo C2-6, donde alquilo C1-6, alquenilo C2-6, y alquinilo C2-6 están sustituidos opcionalmente con uno o más halogenos que son iguales o diferentes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09173535 | 2009-10-20 | ||
US37535810P | 2010-08-20 | 2010-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR078675A1 true AR078675A1 (es) | 2011-11-23 |
Family
ID=41531257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100103813A AR078675A1 (es) | 2009-10-20 | 2010-10-19 | Derivados de pirazolo[3,4-d]pirimidina inhibidores de jak quinasas, composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos para el tratamiento o profilaxis de trastornos inmunologicos, inflamatorios y autoinmunes. |
Country Status (15)
Country | Link |
---|---|
US (1) | US9242987B2 (es) |
EP (1) | EP2491039A1 (es) |
JP (1) | JP5744887B2 (es) |
KR (1) | KR20120102601A (es) |
CN (1) | CN102666545B (es) |
AR (1) | AR078675A1 (es) |
AU (1) | AU2010309882B2 (es) |
BR (1) | BR112012009327A2 (es) |
CA (1) | CA2775009A1 (es) |
EA (1) | EA022120B1 (es) |
IL (1) | IL218751A0 (es) |
MX (1) | MX2012004020A (es) |
NZ (1) | NZ598907A (es) |
TW (1) | TW201125867A (es) |
WO (1) | WO2011048082A1 (es) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103214483B (zh) | 2005-12-13 | 2014-12-17 | 因塞特公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
CN102271515B (zh) | 2008-10-31 | 2014-07-02 | 健泰科生物技术公司 | 吡唑并嘧啶jak抑制剂化合物和方法 |
DK2432472T3 (da) | 2009-05-22 | 2019-11-18 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer |
PL2448938T3 (pl) | 2009-06-29 | 2014-11-28 | Incyte Holdings Corp | Pirymidynony jako inhibitory PI3K |
UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
KR102283091B1 (ko) | 2010-03-10 | 2021-07-30 | 인사이트 홀딩스 코포레이션 | Jak1 저해제로서의 피페리딘4일 아제티딘 유도체 |
WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
EP2574168B9 (en) | 2010-05-21 | 2016-10-05 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
JP2013534233A (ja) * | 2010-08-20 | 2013-09-02 | セルゾーム リミティッド | 選択的jak阻害剤としてのヘテロシクリルピラゾロピリミジン類似体 |
WO2012035039A1 (en) | 2010-09-15 | 2012-03-22 | F. Hoffmann-La Roche Ag | Azabenzothiazole compounds, compositions and methods of use |
WO2012066061A1 (en) * | 2010-11-19 | 2012-05-24 | F. Hoffmann-La Roche Ag | Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors |
AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
JP5961187B2 (ja) | 2010-12-20 | 2016-08-02 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
WO2012143320A1 (en) | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
WO2013014162A1 (en) | 2011-07-28 | 2013-01-31 | Cellzome Limited | Heterocyclyl pyrimidine analogues as jak inhibitors |
WO2013017479A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
HUE030869T2 (en) | 2011-09-02 | 2017-06-28 | Incyte Holdings Corp | Heterocyclic amines as inhibitors of PI3K |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
CA2849340A1 (en) | 2011-09-20 | 2013-03-28 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors |
KR20140114344A (ko) | 2011-12-23 | 2014-09-26 | 셀좀 리미티드 | 키나제 억제제로서의 피리미딘-2,4-디아민 유도체 |
CN103193600B (zh) * | 2012-01-07 | 2016-04-06 | 浙江九洲药物科技有限公司 | 卡巴拉汀中间体的制备方法 |
ES2655264T3 (es) | 2012-01-28 | 2018-02-19 | Merck Patent Gmbh | Derivados de triazolo[4,5-d]pirimidina |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
WO2013174895A1 (en) | 2012-05-24 | 2013-11-28 | Cellzome Limited | Heterocyclyl pyrimidine analogues as tyk2 inhibitors |
CR20190073A (es) | 2012-11-15 | 2019-04-25 | Incyte Holdings Corp | FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265) |
AU2014208964B2 (en) | 2013-01-23 | 2016-09-01 | Astrazeneca Ab | Chemical compounds |
RS62867B1 (sr) | 2013-03-06 | 2022-02-28 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
EP3030227B1 (en) | 2013-08-07 | 2020-04-08 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
US20160222014A1 (en) * | 2013-09-10 | 2016-08-04 | Asana Biosciences, Llc | Compounds for regulating fak and/or src pathways |
MX2016004945A (es) | 2013-10-17 | 2016-06-28 | Dow Agrosciences Llc | Procesos para la preparacion de compuestos plaguicidas. |
UA121658C2 (uk) | 2014-05-23 | 2020-07-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки 5-хлордифторметоксифенілпіразолопіримідину як інгібітори янус-кінази |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
JP6499282B2 (ja) | 2014-09-26 | 2019-04-10 | ギリアード サイエンシーズ, インコーポレイテッド | Tank結合キナーゼ阻害剤化合物として有用なアミノトリアジン誘導体 |
AU2016222556B2 (en) | 2015-02-27 | 2020-08-27 | Incyte Holdings Corporation | Salts of Pl3K inhibitor and processes for their preparation |
CN110078741B (zh) * | 2015-04-24 | 2021-10-01 | 广州再极医药科技有限公司 | 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用 |
WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
AU2016370916A1 (en) | 2015-12-17 | 2018-06-07 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
WO2018022992A1 (en) * | 2016-07-29 | 2018-02-01 | Flx Bio, Inc. | Chemokine receptor modulators and uses thereof |
US10233155B2 (en) | 2016-12-29 | 2019-03-19 | Dow Agrosciences Llc | Processes for the preparation of pesticide compounds |
CN110139853B (zh) | 2016-12-29 | 2023-06-16 | 美国陶氏益农公司 | 用于制备杀有害生物化合物的方法 |
PL233595B1 (pl) * | 2017-05-12 | 2019-11-29 | Celon Pharma Spolka Akcyjna | Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK |
AU2018274577A1 (en) | 2017-05-22 | 2019-10-10 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
CA3083583A1 (en) * | 2017-12-05 | 2019-06-13 | Oscotec Inc. | Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
PE20211310A1 (es) | 2018-01-30 | 2021-07-22 | Incyte Corp | Procedimiento para la elaboracion de un recipiente de vidrio de sosa-cal a partir de materiales formadores de vidrio 100% reciclados y un recipiente de vidrio elaborado a partir de dicho procedimiento |
CA3093781A1 (en) | 2018-02-28 | 2019-09-06 | Basf Se | Use of n-functionalized alkoxy pyrazole compounds as nitrification inhibitors |
CA3089381A1 (en) | 2018-02-28 | 2019-09-06 | Basf Se | Use of pyrazole propargyl ethers as nitrification inhibitors |
JP2021519775A (ja) | 2018-03-30 | 2021-08-12 | インサイト・コーポレイションIncyte Corporation | Jak阻害剤を用いる化膿性汗腺炎の治療 |
CN110885331B (zh) * | 2018-09-11 | 2021-07-09 | 中国药科大学 | 一种6-氨基-1H-吡唑并[3,4-d]嘧啶类JAK激酶抑制剂的制备与应用 |
EP3864001A1 (en) * | 2018-10-11 | 2021-08-18 | Basf As | Romatic compounds and pharmaceutical uses thereof |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
WO2020227563A1 (en) * | 2019-05-08 | 2020-11-12 | Vimalan Biosciences, Inc. | Jak inhibitors |
TW202110849A (zh) * | 2019-05-27 | 2021-03-16 | 大陸商迪哲(江蘇)醫藥股份有限公司 | Dna依賴性蛋白激酶抑制劑 |
US11459333B2 (en) * | 2019-08-08 | 2022-10-04 | Vimalan Biosciences, Inc. | Substituted pyrrolo[2,3-d]pyrimidines as JAK inhibitors |
US20230065636A1 (en) * | 2020-01-15 | 2023-03-02 | KSQ Therapeutics, Inc. | Compositions of substituted pyrazolopyrimidines and uses thereof |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
KR20230098186A (ko) * | 2020-10-30 | 2023-07-03 | 케이에스큐 세러퓨틱스 인코포레이티드 | 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도 |
CN117440946A (zh) | 2021-05-21 | 2024-01-23 | 巴斯夫欧洲公司 | N-官能化的烷氧基吡唑化合物作为硝化抑制剂的用途 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4367866B2 (ja) | 1997-02-12 | 2009-11-18 | ザ リージェンツ オブ ジ ユニバーシティ オブ ミシガン | 肺癌用のタンパク質マーカーおよびその使用 |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
ES2306306T3 (es) | 1999-11-05 | 2008-11-01 | Astrazeneca Ab | Nuevos derivados de quinazolina. |
SK287188B6 (sk) | 1999-12-10 | 2010-02-08 | Pfizer Products Inc. | Pyrolo [2,3-d]pyrimidínová zlúčenina, jej použitie a farmaceutická kompozícia alebo kombinácia s jej obsahom |
CZ303705B6 (cs) | 2000-02-15 | 2013-03-27 | Sugen, Inc. | Pyrrolem substituovaná 2-indolinonová sloucenina pro pouzití jako inhibitor proteinkináz a farmaceutická kompozice s jejím obsahem |
PT1713806E (pt) * | 2004-02-14 | 2013-08-27 | Irm Llc | Compostos e composições como inibidores da proteína quinase |
US7947695B2 (en) * | 2005-01-14 | 2011-05-24 | Janssen Pharmaceutica Nv | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
CA2611365C (en) | 2005-06-14 | 2014-02-11 | Cellzome Ag | Process for the identification of novel enzyme interacting compounds |
GB0605691D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
ES2318616T3 (es) | 2006-06-01 | 2009-05-01 | Cellzome Ag | Metodos para la identificacion de moleculas que interactuan con zap-70 y para la purificacion de zap-70. |
JP2009544592A (ja) | 2006-07-21 | 2009-12-17 | ノバルティス アクチエンゲゼルシャフト | Jakキナーゼ阻害剤としての2,4−ジ(アリールアミノ)−ピリミジン−5−カルボキサミド化合物 |
EP2099800A1 (en) | 2006-11-16 | 2009-09-16 | Pharmacopeia, LLC | 7-substituted purine derivatives for immunosuppression |
AU2008211172A1 (en) * | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | 1-H-pyrazolo(3,4B)pyrimidine derivatives and their use as modulators of mitotic kinases |
WO2008118822A1 (en) | 2007-03-23 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2008118823A2 (en) | 2007-03-26 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US20090274698A1 (en) | 2007-07-06 | 2009-11-05 | Shripad Bhagwat | Combination anti-cancer therapy |
KR20130066703A (ko) * | 2008-02-06 | 2013-06-20 | 노파르티스 아게 | 피롤로[2,3d]피리미딘 및 티로신 키나제 억제제로서 그의 용도 |
CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
CA2758614A1 (en) | 2009-04-14 | 2010-10-21 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
WO2011156698A2 (en) | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
-
2010
- 2010-10-19 EA EA201270572A patent/EA022120B1/ru not_active IP Right Cessation
- 2010-10-19 AU AU2010309882A patent/AU2010309882B2/en not_active Ceased
- 2010-10-19 WO PCT/EP2010/065700 patent/WO2011048082A1/en active Application Filing
- 2010-10-19 CN CN201080058290.5A patent/CN102666545B/zh not_active Expired - Fee Related
- 2010-10-19 NZ NZ598907A patent/NZ598907A/en not_active IP Right Cessation
- 2010-10-19 KR KR1020127009821A patent/KR20120102601A/ko not_active Application Discontinuation
- 2010-10-19 CA CA2775009A patent/CA2775009A1/en not_active Abandoned
- 2010-10-19 MX MX2012004020A patent/MX2012004020A/es not_active Application Discontinuation
- 2010-10-19 BR BR112012009327A patent/BR112012009327A2/pt not_active IP Right Cessation
- 2010-10-19 EP EP10775748A patent/EP2491039A1/en not_active Withdrawn
- 2010-10-19 US US13/503,083 patent/US9242987B2/en not_active Expired - Fee Related
- 2010-10-19 AR ARP100103813A patent/AR078675A1/es unknown
- 2010-10-19 JP JP2012534661A patent/JP5744887B2/ja not_active Expired - Fee Related
- 2010-10-19 TW TW099135495A patent/TW201125867A/zh unknown
-
2012
- 2012-03-20 IL IL218751A patent/IL218751A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20120102601A (ko) | 2012-09-18 |
NZ598907A (en) | 2014-03-28 |
JP5744887B2 (ja) | 2015-07-08 |
TW201125867A (en) | 2011-08-01 |
BR112012009327A2 (pt) | 2017-06-06 |
CN102666545A (zh) | 2012-09-12 |
AU2010309882A1 (en) | 2012-04-12 |
CA2775009A1 (en) | 2011-04-28 |
WO2011048082A1 (en) | 2011-04-28 |
MX2012004020A (es) | 2012-05-08 |
IL218751A0 (en) | 2012-06-28 |
US9242987B2 (en) | 2016-01-26 |
AU2010309882B2 (en) | 2016-01-28 |
JP2013508332A (ja) | 2013-03-07 |
EA201270572A1 (ru) | 2012-12-28 |
EP2491039A1 (en) | 2012-08-29 |
US20120252779A1 (en) | 2012-10-04 |
CN102666545B (zh) | 2016-04-06 |
EA022120B1 (ru) | 2015-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR078675A1 (es) | Derivados de pirazolo[3,4-d]pirimidina inhibidores de jak quinasas, composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos para el tratamiento o profilaxis de trastornos inmunologicos, inflamatorios y autoinmunes. | |
HRP20161674T1 (hr) | 4-(8-METOKSI-1-((1-METOKSIPROPAN-2-IL)-2-(TETRAHIDRO-2H-PIRAN-4-IL)-1H-IMIDAZO[4,5-c]KINOLIN-7-IL)-3,5-DIMETILIZOKSAZOL I NJEGOVA UPOTREBA KAO INHIBITORA BROMODOMENE | |
AR083071A1 (es) | Uso de analogos de nucleosidos y nucleotidos para tratar infecciones virales por paramixovirus y/o ortomixovirus, compuestos relacionados y composiciones farmaceuticas que los contienen | |
ECSP099436A (es) | Acilaminopirazoles como inhibidores de fgfr | |
ECSP077412A (es) | Derivados de indol tetracíclicos como agentes antivíricos | |
CR20140084A (es) | Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 | |
AR049126A1 (es) | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. | |
ECSP12011684A (es) | Inhibidores de los virus flaviviridae. | |
CO6541645A2 (es) | Compuestos de indol y su uso farmaceutico | |
AR062503A1 (es) | Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor. | |
WO2008142720A3 (en) | Quinazolin-oxime derivatives as hsp90 inhibitors | |
SV2011004077A (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
DK3372281T3 (da) | Polycyklisk carbamoylpyridon-derivat med HIV-integrase-hæmmende aktivitet | |
AR047527A1 (es) | 2-halogenofuril/tienil-3-carboxamidas | |
AR076550A1 (es) | Inhibidores de la janus tirosina kinasa (jak) | |
ES2651150T3 (es) | Análogos de heterociclilpirimidina como inhibidores de TYK2 | |
EA201270540A1 (ru) | Макроциклические ингибиторы интегразы | |
AR116315A1 (es) | Compuestos de triazolo-pirimidina y usos de los mismos | |
UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
BRPI0821255A2 (pt) | Derivados de espiroindolinona | |
ECSP066693A (es) | Derivados de bencimidazol | |
AR082633A1 (es) | Analogos de tetraciclina | |
AR068528A1 (es) | Formas solidas de n-(5-tert-butil-isoxazol-3-il)-n'-(4(7-(2-morfolin-4-il-etoxi) imidazol(2,1-b)(1,3)benzotiazol-2-il)fenil)urea, composiciones con las mismas y usos de los mismos | |
JP2012512158A5 (es) | ||
AR056218A1 (es) | Composicion farmaceutica de liberacion mantenida comprimido de liberacion inmediata y comprimido oralmente administrable que comprende una sla soluble en agua d 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2- hidroxi-1-(hidroximetil)etil] amino}pirido (2,3-d)pirimidin-7(8h)-ona; dicho compues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |